

Biotinylated Human IL-23A&IL-12B Heterodimer Protein; His-Avi Tag

Product Information

| Product Name | Biotinylated Human IL-23A&IL-12B Heterodimer Protein; His-Avi Tag |
|-----------------|---|
| Storage temp. | Store at \leq -70°C, stable for 6 months after receipt. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Catalog# / Size | GM-88026RP-25 / 25 µg GM-88026RP-200 / 200 µg |

Protein Information

| Alternative Names | IL-23 alpha & IL-12 beta Heterodimer | | |
|--------------------|--|--|--|
| Source | Biotinylated Human IL-23A&IL-12B Heterodimer Protein; His-Avi Tag (GM- | | |
| | 88026RP) is expressed from human 293 cells (HEK-293). It contains AA(IL- | | |
| | 23A) Arg 20 - Pro 189 (Accession # Q9NPF7-1) and AA(IL-12B) Ile 23 - Ser 328 (Accession # P29460-1). | | |
| | | | |
| | This protein carries a His-Avi tag at the C-terminus of IL-12B. | | |
| Purity | > 95% as determined by SDS-PAGE | | |
| Endotoxin | < 1 EU/µg, determined by LAL gel clotting assay | | |
| Predicted Mol Mass | 18.7 KDa (IL-23A) and 36.2 KDa (IL-12B) | | |
| Formulation | Supplied as a 0.2 µm filtered solution of PBS, pH7.2-7.4. | | |
| Description | IL-23 is a heterodimeric cytokine made of IL-23 alpha (p19) and IL-12 beta (p40) | | |
| | subunits. While p40 is shared with IL-12, p19 is unique to IL-23. It binds to its | | |
| | receptor complex (IL-23R and IL-12R β 1) to regulate Th17 cells, promoting the | | |
| | release of pro-inflammatory cytokines like IL-17 and IL-22, driving immune | | |
| | inflammation. | | |
| | IL-23 plays a significant role in many inflammatory and autoimmune diseases, | | |
| | such as psoriasis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis. Due | | |
| | to its regulation of Th17 cells and inflammatory responses, IL-23 has become an | | |
| | important therapeutic target. Drugs that specifically block p19 (e.g., guselkumab) | | |
| | have been used to treat various inflammatory diseases. Additionally, p40- | | |
| | targeting drugs (e.g., ustekinumab) can inhibit the functions of both IL-12 and IL- | | |
| | 23, thereby alleviating disease progression. | | |




Genomeditech (Shanghai) Co.,Ltd. Order: 021-68455258/50432826/50432825 Toll-free: 400 627 9288 Email: service@genomeditech.com

SDS-PAGE

| kDa | Μ | R |
|----------|---|---|
| 250 | - | |
| 130 | - | |
| 100 | - | |
| 65 | - | |
| 50 | - | |
| 40 | - | |
| 30 | - | |
| 25 | - | |
| 20 | - | |
| 15 10 | = | |

On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA



Biotinylated Human IL-23A&IL-12B Heterodimer Protein; His-Avi Tag (Catalog # GM-88026RP) was immobilized at 2 μ g/ml (100 μ L/well) on streptavidin precoated. Increasing concentrations of Anti-IL-12/23(p40) hIgG1 Reference Antibody (Ustebio) (Catalog # GM-87870MAB) were added.